source
- The Supreme Court won't take up drugmakers' IRA casesThe Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The justices declined to review multiple cases brought by AstraZeneca,…Endpoints · 2mo ago↗ source
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much moreThe question of whether to partner with Chinese firms — or see them as rivals — is tearing biotech apart, pitting peers and partners against one anotherSTAT · 2mo ago↗ source
- Regeneron immunotherapy combo comes up short in melanoma trialA two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in marke…